Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e21058-e21058
Author(s):  
Elisa A. Rozeman ◽  
Yanina Jansen ◽  
MarnixMarnix Heimen Geukes Foppen ◽  
Max Schreuer ◽  
Sofie Wilgenhof ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Advanced Melanoma ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Baseline Characteristics ◽  
Access Program

Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma

2013 ◽  
Vol 36 (3) ◽  
pp. 215-222 ◽  
Author(s):  
Sofie Wilgenhof ◽  
Stephanie Du Four ◽  
Frederik Vandenbroucke ◽  
Hendrik Everaert ◽  
Isabelle Salmon ◽  
...  
Keyword(s):  
Advanced Melanoma ◽  
Single Center ◽  
Expanded Access ◽  
Single Center Experience ◽  
Expanded Access Program ◽  
Access Program

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

2017 ◽  
Vol 19 (6) ◽  
pp. 761-768 ◽  
Author(s):  
M. González-Cao ◽  
◽  
A. Arance ◽  
J. M. Piulats ◽  
I. Marquez-Rodas ◽  
...  
Keyword(s):  
Advanced Melanoma ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9525-9525 ◽  
Author(s):  
Paul B. Chapman ◽  
Mario Sznol ◽  
Christopher Lao ◽  
Rene Gonzalez ◽  
Gregory A. Daniels ◽  
...  
Keyword(s):  
Safety Data ◽  
Advanced Melanoma ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program
Sign in / Sign up

Export Citation Format

Share Document